Emi Harris
Family · San Diego, CANPI 1134769573
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,982 of the $4,479 with a category attached, or 88.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,221, 8.7 times the $255 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $29.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$833
- AbbVie$564
- Bristol Myers Squibb$235
- AstraZeneca$218
- Pfizer$212
- Tersera Therapeutics LLC$204
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$301%
- Food & beverage$3,98289%
- Education$46710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 22 | $833 |
| AbbVie | 33 | $564 |
| Bristol Myers Squibb | 6 | $235 |
| AstraZeneca | 5 | $218 |
| Pfizer | 9 | $212 |
| Tersera Therapeutics LLC | 6 | $204 |
| E.r. Squibb & Sons, L.L.C. | 5 | $194 |
| Genmab U.S., Inc. | 6 | $181 |
| Merck | 6 | $170 |
| Incyte Corporation | 2 | $140 |
| Pharmaessentia USA Corporation | 4 | $130 |
| Karyopharm Therapeutics Inc. | 1 | $118 |
| Genentech USA, Inc. | 4 | $115 |
| Jazz Pharmaceuticals Inc. | 3 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Stemline Therapeutics Inc. | 2 | $76 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Gilead | 3 | $71 |
| GSK | 3 | $67 |
| Rigel Pharmaceuticals, Inc. | 3 | $64 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Coherus Oncology, Inc. | 2 | $52 |
| Boehringer Ingelheim | 2 | $47 |
| Acrotech Biopharma Inc. | 2 | $39 |
| UCB, Inc. | 1 | $36 |
| BD | 1 | $30 |
| Pharmacosmos Therapeutics Inc. | 1 | $29 |
| Novartis | 1 | $28 |
| Beigene USA, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| EMD Serono, Inc. | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,479 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine-PrilocaineLidocaine/Prilocaine | 23 | $242 |
| Dexamethasone | 12 | $129 |
Paid to pharmacies, not to this prescriber.
Other family in San Diego
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
- Phyllis CasonLos Angeles$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.